Atara transferred the BLA to Pierre Fabre, which already handles manufacturing, regulatory, and commercial activities for Ebvallo in Europe.
The firm will use proceeds to complete clinical proof of concept of its lead gene therapy programs in rare, inherited retinal diseases.
Researchers presented new data on Phenomix Sciences' genetic risk scores at the Obesity Society's ObesityWeek conference.
Sales of the leukemia drug Blincyto grew 20 percent to $392 million, but Lumakras sales decreased 2 percent to $96 million, compared to Q3 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback